These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19494061)

  • 21. High prevalence of multidrug resistant ESBL- and plasmid mediated AmpC-producing clinical isolates of Escherichia coli at Maputo Central Hospital, Mozambique.
    Estaleva CEL; Zimba TF; Sekyere JO; Govinden U; Chenia HY; Simonsen GS; Haldorsen B; Essack SY; Sundsfjord A
    BMC Infect Dis; 2021 Jan; 21(1):16. PubMed ID: 33407206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of CLSI and EUCAST Cefepime breakpoint changes on the susceptibility reporting for Enterobacteriaceae.
    Bork JT; Heil EL; Leekha S; Fowler RC; Hanson ND; Majumdar A; Johnson JK
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):328-333. PubMed ID: 29031525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
    Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
    J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan.
    Matsumura Y; Yamamoto M; Higuchi T; Komori T; Tsuboi F; Hayashi A; Sugimoto Y; Hotta G; Matsushima A; Nagao M; Takakura S; Ichiyama S
    Int J Antimicrob Agents; 2012 Aug; 40(2):158-62. PubMed ID: 22743014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening and confirmatory testing for extended spectrum beta-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates.
    Hadziyannis E; Tuohy M; Thomas L; Procop GW; Washington JA; Hall GS
    Diagn Microbiol Infect Dis; 2000 Feb; 36(2):113-7. PubMed ID: 10705053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
    Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.
    Queenan AM; Foleno B; Gownley C; Wira E; Bush K
    J Clin Microbiol; 2004 Jan; 42(1):269-75. PubMed ID: 14715764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotypes and cephalosporin susceptibility in extended-spectrum beta-lactamase producing enterobacteriaceae in the community.
    Maina D; Revathi G; Kariuki S; Ozwara H
    J Infect Dev Ctries; 2012 Jun; 6(6):470-7. PubMed ID: 22706188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The presence of extended spectrum beta-lactamase, KPC-type carbapenemase and plasmid-mediated AmpC beta-lactamase in E.coli and K.pneumoniae strains isolated from blood cultures].
    Baykal A; Cöplü N; Simşek H; Esen B; Gür D
    Mikrobiyol Bul; 2012 Apr; 46(2):159-69. PubMed ID: 22639305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and distribution of beta-lactamase coding genes in third-generation cephalosporin-resistant Enterobacteriaceae from bloodstream infections in Cambodia.
    Vlieghe ER; Huang TD; Phe T; Bogaerts P; Berhin C; De Smet B; Peetermans WE; Jacobs JA; Glupczynski Y
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1223-9. PubMed ID: 25717021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased expression levels of chromosomal AmpC β-lactamase in clinical Escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins.
    Paltansing S; Kraakman M; van Boxtel R; Kors I; Wessels E; Goessens W; Tommassen J; Bernards A
    Microb Drug Resist; 2015 Feb; 21(1):7-16. PubMed ID: 25188329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.
    McWilliams CS; Condon S; Schwartz RM; Ginocchio CC
    J Clin Microbiol; 2014 Jul; 52(7):2653-5. PubMed ID: 24789185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
    Hombach M; Mouttet B; Bloemberg GV
    J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Enterobacteriaceae producing CTX-M extended spectrum beta-lactamases from a tertiary care hospital in south India.
    Baby Padmini S; Appala Raju B; Mani KR
    Indian J Med Microbiol; 2008; 26(2):163-6. PubMed ID: 18445956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of extended-spectrum beta-lactamases by using boronic acid as an AmpC beta-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli.
    Song W; Bae IK; Lee YN; Lee CH; Lee SH; Jeong SH
    J Clin Microbiol; 2007 Apr; 45(4):1180-4. PubMed ID: 17301276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence study of plasmid-mediated AmpC β-lactamases in Enterobacteriaceae lacking inducible ampC from Saudi hospitals.
    Abdalhamid B; Albunayan S; Shaikh A; Elhadi N; Aljindan R
    J Med Microbiol; 2017 Sep; 66(9):1286-1290. PubMed ID: 28820112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of AmpC and other beta-lactamases in enterobacteria at a large urban university hospital in Brazil.
    da Silva Dias RC; Borges-Neto AA; D'Almeida Ferraiuoli GI; de-Oliveira MP; Riley LW; Moreira BM
    Diagn Microbiol Infect Dis; 2008 Jan; 60(1):79-87. PubMed ID: 17900845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut.
    Tenover FC; Mohammed MJ; Gorton TS; Dembek ZF
    J Clin Microbiol; 1999 Dec; 37(12):4065-70. PubMed ID: 10565933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
    Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.